Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Net Income (2017 - 2025)

Historic Net Income for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$18.9 million.

  • Vistagen Therapeutics' Net Income fell 3414.01% to -$18.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$67.0 million, marking a year-over-year decrease of 4173.43%. This contributed to the annual value of -$51.4 million for FY2025, which is 7511.75% down from last year.
  • Vistagen Therapeutics' Net Income amounted to -$18.9 million in Q4 2025, which was down 3414.01% from -$19.4 million recorded in Q3 2025.
  • Vistagen Therapeutics' Net Income's 5-year high stood at -$6.2 million during Q1 2021, with a 5-year trough of -$19.8 million in Q2 2022.
  • Moreover, its 5-year median value for Net Income was -$12.5 million (2021), whereas its average is -$12.4 million.
  • In the last 5 years, Vistagen Therapeutics' Net Income plummeted by 28798.59% in 2021 and then surged by 6509.46% in 2023.
  • Vistagen Therapeutics' Net Income (Quarter) stood at -$10.5 million in 2021, then rose by 7.34% to -$9.8 million in 2022, then surged by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then tumbled by 34.14% to -$18.9 million in 2025.
  • Its Net Income stands at -$18.9 million for Q4 2025, versus -$19.4 million for Q3 2025 and -$15.1 million for Q2 2025.